Scholar Rock (SRRK)
| Bid | 31.98 |
| Market Cap | 3.12B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -246.29M |
| EPS (ttm) | -2.47 |
| PE Ratio (ttm) | -13.3 |
| Forward PE | -27.29 |
| Analyst | Buy |
| Ask | 35.95 |
| Volume | 799,240 |
| Avg. Volume (20D) | 1,315,924.3 |
| Open | 33.33 |
| Previous Close | 32.91 |
| Day's Range | 32.23 - 33.33 |
| 52-Week Range | 6.76 - 46.98 |
| Beta | 0.58 |
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical tria...
Analyst Forecast
According to 6 analyst ratings, the average rating for SRRK stock is "Buy." The 12-month stock price forecast is $43.5, which is an increase of 32.44% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call TranscriptScholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco -...
